Ruboxistaurin
Template:Short description Template:Drugbox Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.
In February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an approvable letter from the US FDA for ruboxistaurin,[1] with a request for an additional clinical trial, which would take 5 years to complete.[2] Lilly has not made any further request for approval and ruboxistaurin is not approved by the FDA for any medical use.[3]
Mechanism of action
Ruboxistaurin is an inhibitor of protein kinase C-beta.[4]
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".